Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Saved in:
| Title: | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. |
|---|---|
| Authors: | Matsumoto T; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. makoharutaro2015@gmail.com.; Cancer Treatment Center, Kansai Medical University, 2‑3‑1, Hirakatashinmachi, Hirakata, Osaka, 573‑1191, Japan. makoharutaro2015@gmail.com., Ikoma T; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Yamamura S; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Miura K; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Tsuduki T; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Watanabe T; Department of Surgery, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Nagai H; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Takatani M; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Yasui H; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. |
| Source: | Scientific reports [Sci Rep] 2023 Jul 24; Vol. 13 (1), pp. 11935. Date of Electronic Publication: 2023 Jul 24. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-023-39009-5 |
